The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age
Open accessAbstract
BACKGROUND: Previous analyses from a randomised trial in women aged 24-45 years have shown the quadrivalent human papillomavirus (qHPV) vaccine to be efficacious in the prevention of infection, cervical intraepithelial neoplasia (CIN), and external genital lesions (EGLs) related to HPV 6/11/16/18. In this report, we present end-of-study efficacy, safety, and immunogenicity data with a median follow-up time of 4.0 years. METHODS: We enrolled 3819 24-45-year-old women with no history of cervical disease or genital warts in the past 5 years. Women received quadrivalent vaccine or placebo at day 1, and at months 2 and 6. Ascertainment of CIN/EGL was accomplished through Pap testing, genital inspection, and cervicovaginal sampling (every 6 months). The main analysis was conducted in a per-protocol efficacy population (that received three doses, was naive to the relevant HPV types at day 1, and remained free of infection through month 7). Efficacy was also estimated in other naive and non-naive populations. RESULTS: Vaccine efficacy against the combined incidence of persistent infection, CIN/EGL related to HPV6/11/16/18 in the per-protocol population was 88.7% (95% CI: 78.1, 94.8). Efficacy for women who were seropositive and DNA negative for the relevant vaccine HPV type at the time of enrolment who received at least 1 dose was 66.9% (95% CI: 4.3, 90.6). At month 48, 91.5, 92.0, 97.4, and 47.9% of vaccinated women were seropositive to HPV 6/11/16/18, respectively. No serious vaccine-related adverse experiences were reported. CONCLUSIONS: The qHPV vaccine demonstrated high efficacy, immunogenicity, and acceptable safety in women aged 24-45 years, regardless of previous exposure to HPV vaccine type.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IARC Monographs on the Evaluation of Carcinogenic Risks to Humans
Zuckerman, A. J. (1995) · Journal of Clinical Pathology · doi:10.1136/jcp.48.7.691-a · Cited by 8,728
Epidemiologic classification of human papillomavirus types associated with cervical cancer
Muñoz, N., Bosch, F. X., de Sanjosé, S., Herrero, R., Castellsagué, X., Shah, K. V., Snijders, P. J. F., & Meijer, C. J. L. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021641 · Cited by 6,249
Self-citationThe 2001 Bethesda System<SUBTITLE>Terminology for Reporting Results of Cervical Cytology</SUBTITLE>
Solomon, D. (2002) · JAMA · doi:10.1001/jama.287.16.2114 · Cited by 3,104
IARC monographs on the evaluation of carcinogenic risks to humans
Hopkins, J. (1989) · Food and Chemical Toxicology · doi:10.1016/0278-6915(89)90054-9 · Cited by 2,876
Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa061741 · Cited by 2,055
Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases
Garland, S. M., Hernandez-Avila, M., Wheeler, C. M., Perez, G., Harper, D. M., Leodolter, S., Tang, G. W. K., Ferris, D. G., Steben, M., Bryan, J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061760 · Cited by 1,886
Self-citationde Sanjosé, S., Diaz, M., Castellsagué, X., Clifford, G., Bruni, L., Muñoz, N., & Bosch, F. X. (2007) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(07)70158-5 · Cited by 1,669
Self-citationPrevalence of HPV Infection Among Females in the United States
Dunne, E. F., Unger, E. R., Sternberg, M., McQuillan, G., Swan, D. C., Patel, S. S., & Markowitz, L. E. (2007) · JAMA · doi:10.1001/jama.297.8.813 · Cited by 1,579
Chapter 1: HPV in the etiology of human cancer
Muñoz, N., Castellsagué, X., de González, A. B., & Gissmann, L. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.05.115 · Cited by 1,355
Self-citationThe Pap Test and Bethesda 2014
Nayar, R., & Wilbur, D. C. (2015) · Journal of the American Society of Cytopathology · doi:10.1016/j.jasc.2015.03.003 · Cited by 1,144
Clifford, G., Gallus, S., Herrero, R., Muñoz, N., Snijders, P., Vaccarella, S., Anh, P., Ferreccio, C., Hieu, N., Matos, E., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67069-9 · Cited by 1,093
Self-citationThe 2001 Bethesda System: Terminology for Reporting Results of Cervical Cytology
Solomon, D., Davey, D., Kurman, R., Moriarty, A., O’Connor, D., Prey, M., Raab, S., Sherman, M., Wilbur, D., & Wright, T. (2002) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-200208000-00015 · Cited by 822
Chapter 2: Natural History of Anogenital Human Papillomavirus Infection and Neoplasia
Schiffman, M., & Kjaer, S. K. (2003) · JNCI Monographs · doi:10.1093/oxfordjournals.jncimonographs.a003476 · Cited by 513
Muñoz, N., Manalastas, R., Pitisuttithum, P., Tresukosol, D., Monsonego, J., Ault, K., Clavel, C., Luna, J., Myers, E., Hood, S., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60691-7 · Cited by 478
Self-citationOlsson, S.-E., Villa, L. L., Costa, R. L. R., Petta, C. A., Andrade, R. P., Malm, C., Iversen, O.-E., Høye, J., Steinwall, M., Riis-Johannessen, G., et al. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.03.049 · Cited by 454
Self-citationMuñoz, N., Méndez, F., Posso, H., Molano, M., van den Brule, A. J. C., Ronderos, M., Meijer, C., Muñoz, Á., & Instituto Nacional de Cancerología HPV study group (2004) · The Journal of Infectious Diseases · doi:10.1086/425907 · Cited by 395
Self-citationRodriguez, A. C., Schiffman, M., Herrero, R., Hildesheim, A., Bratti, C., Sherman, M. E., Solomon, D., Guillen, D., Alfaro, M., Morales, J., et al. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq001 · Cited by 383
Jacobs, M. V., Walboomers, J. M. M., Snijders, P. J. F., Voorhorst, F. J., Verheijen, R. H. M., Fransen-Daalmeijer, N., & Meijer, C. J. L. M. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20000715)87:2<221::aid-ijc11>3.0.co;2-2 · Cited by 277
Opalka, D., Lachman, C. E., MacMullen, S. A., Jansen, K. U., Smith, J. F., Chirmule, N., & Esser, M. T. (2003) · Clinical and Vaccine Immunology · doi:10.1128/cdli.10.1.108-115.2003 · Cited by 276
Joura, E. A., Kjaer, S. K., Wheeler, C. M., Sigurdsson, K., Iversen, O.-E., Hernandez-Avila, M., Perez, G., Brown, D. R., Koutsky, L. A., Tay, E. H., et al. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.09.073 · Cited by 198
Self-citationThe FUTURE II Study Group (2007) · The Journal of Infectious Diseases · doi:10.1086/522864 · Cited by 182
Human papillomavirus in a necessary cause of invasive cervical cancer worldwide
(1999) · Pure Amsterdam UMC · doi:10.1002/(sici)1096-9896(199909)189:1 · Cited by 140
Castellsagué, X., Schneider, A., Kaufmann, A. M., & Bosch, F. X. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.09.021 · Cited by 112
Self-citationProgression and regression of incident cervical HPV 6, 11, 16 and 18 infections in young women
Insinga, R. P., Dasbach, E. J., Elbasha, E. H., Liaw, K., & Barr, E. (2007) · Infectious Agents and Cancer · doi:10.1186/1750-9378-2-15 · Cited by 80
Preliminary HPV vaccine results for women older than 25 years
Harper, D. M. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61045-x · Cited by 20
Cited by
Meites, E., Szilagyi, P. G., Chesson, H. W., Unger, E. R., Romero, J. R., & Markowitz, L. E. (2019) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6832a3 · Cited by 1,025
Carcinogenic human papillomavirus infection
Schiffman, M., Doorbar, J., Wentzensen, N., de Sanjosé, S., Fakhry, C., Monk, B. J., Stanley, M. A., & Franceschi, S. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.86 · Cited by 999
A review of clinical trials of human papillomavirus prophylactic vaccines
Schiller, J. T., Castellsagué, X., & Garland, S. M. (2012) · Vaccine · doi:10.1016/j.vaccine.2012.04.108 · Cited by 747
Self-citationArbyn, M., Xu, L., Simoens, C., & Martin-Hirsch, P. P. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009069.pub3 · Cited by 621
HPV vaccines – A review of the first decade
Harper, D. M., & DeMars, L. R. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.04.004 · Cited by 429
Metadata
- Authors
- Castellsagué, X., Muñoz, N., Pitisuttithum, P., Ferris, D., Monsonego, J., Ault, K., Luna, J., Myers, E., Mallary, S., Bautista, O. M., Bryan, J., Vuocolo, S., Haupt, R. M., & Saah, A.
- Venue
- British Journal of Cancer
- Published
- 2011-05-31
- Volume
- 105
- Issue
- 1
- Pages
- 28-37
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W1975989709
- Cited by
- 347
- References
- 25
- FWCI
- 19.67
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.